Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Colistimethate sodium inhaled - Zambon

Next Previous
Drug Profile

Colistimethate sodium inhaled - Zambon

Alternative Names: Inhaled colistimethate sodium - Zambon; Promixin; ZP 044

Latest Information Update: 04 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Profile Pharma
  • Developer Zambon SpA
  • Class Antibacterials; Polymixins
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Phase III Pseudomonal infections

Most Recent Events

  • 04 Feb 2026 Colistimethate sodium inhaled is still in phase III development for in Pseudomonal infections in Canada, Argentina and USA (NCT03460704)
  • 04 Feb 2026 Colistimethate sodium inhaled is still in phase III development for in Pseudomonal infections in Switzerland, Netherlands and Greece ((NCT03460704)
  • 18 Jul 2023 Zambon terminates a phase III PROMIS II trial in Pseudomonal infections in USA, Argentina, Canada, France, New Zealand, Poland, Portugal, Germany, Greece, Australia, Israel and Italy (Inhalation, Liquid) due to both the COVID-19 pandemic and the view of investigators (EudraCT2016-004558-13) (NCT03460704)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top